Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients ...

Findings from two breakthrough studies reveal positive outcomes for two medications - orfoglipron and MariTide (maridebart cafraglutide) – expanding the treatment of type two diabetes and obesity.